BACKGROUND: Chronic users of cannabis often report withdrawal symptoms after abstinence from use, but little is known about cannabis withdrawal in people with schizophrenia. METHODS: Cannabis use patterns and withdrawal symptoms in adults with schizophrenia who had at least weekly cannabis use before attempting to quit without formal treatment were assessed with the Marijuana Quit Questionnaire (MJQQ), a 176-item, semi-structured questionnaire. RESULTS: 120 participants, predominantly African-American (62.5%) and male (76.7%), met inclusion criteria. 20.1% reported that their first regular cannabis use (median age 15 years [range 8-48]) preceded their age at first psychotic symptoms (20 [4-50] years). Twenty (16.7%) participants met lifetime criteria for cannabis abuse; 98 (81.7%) met surrogate criteria for lifetime cannabis dependence. Withdrawal symptoms were reported by 113 (94.2%) participants, with 74.2% reporting ≥4 symptoms. The most frequently reported withdrawal symptoms were craving for cannabis (59.2%), feeling anxious (52.57%), feeling bored (47.5%), feeling sad or depressed (45.8%), feeling irritable or jumpy (45.0%), feeling restless (43.3%), and trouble failing asleep (33.3%). One hundred-and-four (92.0%) participants took some action to relieve at least one of their withdrawal symptoms during their index-quit attempt, including 26 (23.0%) participants who reported resuming cannabis use. CONCLUSION: Cannabis withdrawal is a clinically significant feature of cannabis use among people with schizophrenia, may serve as a negative reinforcer for relapse, and deserves greater attention in treatment and research. Clinical Trials registration NCT00679016. Published by Elsevier Ltd.
BACKGROUND: Chronic users of cannabis often report withdrawal symptoms after abstinence from use, but little is known about cannabis withdrawal in people with schizophrenia. METHODS: Cannabis use patterns and withdrawal symptoms in adults with schizophrenia who had at least weekly cannabis use before attempting to quit without formal treatment were assessed with the Marijuana Quit Questionnaire (MJQQ), a 176-item, semi-structured questionnaire. RESULTS: 120 participants, predominantly African-American (62.5%) and male (76.7%), met inclusion criteria. 20.1% reported that their first regular cannabis use (median age 15 years [range 8-48]) preceded their age at first psychotic symptoms (20 [4-50] years). Twenty (16.7%) participants met lifetime criteria for cannabis abuse; 98 (81.7%) met surrogate criteria for lifetime cannabis dependence. Withdrawal symptoms were reported by 113 (94.2%) participants, with 74.2% reporting ≥4 symptoms. The most frequently reported withdrawal symptoms were craving for cannabis (59.2%), feeling anxious (52.57%), feeling bored (47.5%), feeling sad or depressed (45.8%), feeling irritable or jumpy (45.0%), feeling restless (43.3%), and trouble failing asleep (33.3%). One hundred-and-four (92.0%) participants took some action to relieve at least one of their withdrawal symptoms during their index-quit attempt, including 26 (23.0%) participants who reported resuming cannabis use. CONCLUSION: Cannabis withdrawal is a clinically significant feature of cannabis use among people with schizophrenia, may serve as a negative reinforcer for relapse, and deserves greater attention in treatment and research. Clinical Trials registration NCT00679016. Published by Elsevier Ltd.
Authors: Marc L Copersino; Susan J Boyd; Donald P Tashkin; Marilyn A Huestis; Stephen J Heishman; John C Dermand; Michael S Simmons; David A Gorelick Journal: Am J Addict Date: 2006 Jan-Feb
Authors: Deborah S Hasin; Katherine M Keyes; Donald Alderson; Shuang Wang; Efrat Aharonovich; Bridget F Grant Journal: J Clin Psychiatry Date: 2008-09-09 Impact factor: 4.384
Authors: Jennifer H Barnett; Ursula Werners; Sandra M Secher; Katherine E Hill; Rossa Brazil; Kim Masson; David E Pernet; James B Kirkbride; Graham K Murray; Ed T Bullmore; Peter B Jones Journal: Br J Psychiatry Date: 2007-06 Impact factor: 9.319
Authors: Maju Mathew Koola; Deanna L Kelly; Robert P McMahon; Douglas L Boggs; Fang Liu; David A Gorelick Journal: Prim Care Companion CNS Disord Date: 2016-09-01
Authors: Emeline Chauchard; Kenneth H Levin; Marc L Copersino; Stephen J Heishman; David A Gorelick Journal: Addict Behav Date: 2013-04-16 Impact factor: 3.913
Authors: Maju Mathew Koola; Douglas Lee Boggs; Deanna Lynn Kelly; Fang Liu; Jared Allen Linthicum; Hailey Elaine Turner; Robert Patrick McMahon; David Alan Gorelick Journal: Psychiatry Res Date: 2013-08-20 Impact factor: 3.222